Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667810 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 901
- Enrollment target
NCT00667810 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 901 participants.
The verdict
NCT00667810, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 901 participants
- Enrollment target
Study Summary
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.
Interventions
- DRUG placebo
- DRUG bapineuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 901 participants |
| Start Date | 2008-06 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667810
The ClinicalTrials.gov registry entry for NCT00667810 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 901 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00667810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667810 about?
NCT00667810 is a clinical study titled "Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients". This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.
What is the current status of trial NCT00667810?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 901 participants. The study started on 2008-06. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00667810?
The interventions under investigation include: placebo (DRUG), bapineuzumab (DRUG).
Who is sponsoring clinical trial NCT00667810?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.